Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis

Hideo Morioka, Lawrence Weissbach, Tikva Vogel, G. Petur Nielsen, Glynn T. Faircloth, Li Shao, Francis J. Hornicek

研究成果: Article

69 引用 (Scopus)

抄録

A combination therapy protocol using a marine chemotherapeutic and an antiangiogenic molecule was tested in a mouse tumor xenograft model for the ability to curtail the growth of a human chondrosarcoma (CHSA). Ecteinascidin-743 (ET-743), a marine-derived chemotherapeutic, was effective at slowing the growth of a primary CHSA. Plasminogen-related protein B, which antagonizes various endothelial cell activities, also elicited a significant inhibition of neoplastic growth, albeit with reduced effectiveness. The combination of the two agents resulted in only a modest further repression of tumor growth over that associated with ET-743 treatment alone, as measured by tumor volume (82% versus 76% inhibition, respectively). However, analysis of the extent of tumor necrosis and vascularization of the tumor revealed that the coadministration of the two compounds was clearly more effective, eliciting a 2.5-fold increase in tumor necrosis relative to single-agent treatment. The combination therapy also was most effective at antagonizing tumor-associated microvessel formation, as assessed by CD31 immunostaining, suggesting that combination therapy may hold promise for treating CHSA. Tumor necrosis produced by combination therapy of ET-743 and recombinant plasminogen-related protein B was also significantly greater than that produced by conventional doxorubicin treatment, further corroborating the efficacy of combination therapy.

元の言語English
ページ(範囲)1211-1217
ページ数7
ジャーナルClinical Cancer Research
9
発行部数3
出版物ステータスPublished - 2003 3 1

Fingerprint

Chondrosarcoma
trabectedin
Necrosis
Drug Therapy
Neoplasms
Plasminogen
Therapeutics
Growth
Microvessels
Tumor Burden
Heterografts
Doxorubicin
Endothelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Morioka, H., Weissbach, L., Vogel, T., Nielsen, G. P., Faircloth, G. T., Shao, L., & Hornicek, F. J. (2003). Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clinical Cancer Research, 9(3), 1211-1217.

Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. / Morioka, Hideo; Weissbach, Lawrence; Vogel, Tikva; Nielsen, G. Petur; Faircloth, Glynn T.; Shao, Li; Hornicek, Francis J.

:: Clinical Cancer Research, 巻 9, 番号 3, 01.03.2003, p. 1211-1217.

研究成果: Article

Morioka, H, Weissbach, L, Vogel, T, Nielsen, GP, Faircloth, GT, Shao, L & Hornicek, FJ 2003, 'Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis', Clinical Cancer Research, 巻. 9, 番号 3, pp. 1211-1217.
Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, Shao L その他. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clinical Cancer Research. 2003 3 1;9(3):1211-1217.
Morioka, Hideo ; Weissbach, Lawrence ; Vogel, Tikva ; Nielsen, G. Petur ; Faircloth, Glynn T. ; Shao, Li ; Hornicek, Francis J. / Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. :: Clinical Cancer Research. 2003 ; 巻 9, 番号 3. pp. 1211-1217.
@article{4edf6f9b3e324b1db7da0895e88d7a09,
title = "Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis",
abstract = "A combination therapy protocol using a marine chemotherapeutic and an antiangiogenic molecule was tested in a mouse tumor xenograft model for the ability to curtail the growth of a human chondrosarcoma (CHSA). Ecteinascidin-743 (ET-743), a marine-derived chemotherapeutic, was effective at slowing the growth of a primary CHSA. Plasminogen-related protein B, which antagonizes various endothelial cell activities, also elicited a significant inhibition of neoplastic growth, albeit with reduced effectiveness. The combination of the two agents resulted in only a modest further repression of tumor growth over that associated with ET-743 treatment alone, as measured by tumor volume (82{\%} versus 76{\%} inhibition, respectively). However, analysis of the extent of tumor necrosis and vascularization of the tumor revealed that the coadministration of the two compounds was clearly more effective, eliciting a 2.5-fold increase in tumor necrosis relative to single-agent treatment. The combination therapy also was most effective at antagonizing tumor-associated microvessel formation, as assessed by CD31 immunostaining, suggesting that combination therapy may hold promise for treating CHSA. Tumor necrosis produced by combination therapy of ET-743 and recombinant plasminogen-related protein B was also significantly greater than that produced by conventional doxorubicin treatment, further corroborating the efficacy of combination therapy.",
author = "Hideo Morioka and Lawrence Weissbach and Tikva Vogel and Nielsen, {G. Petur} and Faircloth, {Glynn T.} and Li Shao and Hornicek, {Francis J.}",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "9",
pages = "1211--1217",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis

AU - Morioka, Hideo

AU - Weissbach, Lawrence

AU - Vogel, Tikva

AU - Nielsen, G. Petur

AU - Faircloth, Glynn T.

AU - Shao, Li

AU - Hornicek, Francis J.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - A combination therapy protocol using a marine chemotherapeutic and an antiangiogenic molecule was tested in a mouse tumor xenograft model for the ability to curtail the growth of a human chondrosarcoma (CHSA). Ecteinascidin-743 (ET-743), a marine-derived chemotherapeutic, was effective at slowing the growth of a primary CHSA. Plasminogen-related protein B, which antagonizes various endothelial cell activities, also elicited a significant inhibition of neoplastic growth, albeit with reduced effectiveness. The combination of the two agents resulted in only a modest further repression of tumor growth over that associated with ET-743 treatment alone, as measured by tumor volume (82% versus 76% inhibition, respectively). However, analysis of the extent of tumor necrosis and vascularization of the tumor revealed that the coadministration of the two compounds was clearly more effective, eliciting a 2.5-fold increase in tumor necrosis relative to single-agent treatment. The combination therapy also was most effective at antagonizing tumor-associated microvessel formation, as assessed by CD31 immunostaining, suggesting that combination therapy may hold promise for treating CHSA. Tumor necrosis produced by combination therapy of ET-743 and recombinant plasminogen-related protein B was also significantly greater than that produced by conventional doxorubicin treatment, further corroborating the efficacy of combination therapy.

AB - A combination therapy protocol using a marine chemotherapeutic and an antiangiogenic molecule was tested in a mouse tumor xenograft model for the ability to curtail the growth of a human chondrosarcoma (CHSA). Ecteinascidin-743 (ET-743), a marine-derived chemotherapeutic, was effective at slowing the growth of a primary CHSA. Plasminogen-related protein B, which antagonizes various endothelial cell activities, also elicited a significant inhibition of neoplastic growth, albeit with reduced effectiveness. The combination of the two agents resulted in only a modest further repression of tumor growth over that associated with ET-743 treatment alone, as measured by tumor volume (82% versus 76% inhibition, respectively). However, analysis of the extent of tumor necrosis and vascularization of the tumor revealed that the coadministration of the two compounds was clearly more effective, eliciting a 2.5-fold increase in tumor necrosis relative to single-agent treatment. The combination therapy also was most effective at antagonizing tumor-associated microvessel formation, as assessed by CD31 immunostaining, suggesting that combination therapy may hold promise for treating CHSA. Tumor necrosis produced by combination therapy of ET-743 and recombinant plasminogen-related protein B was also significantly greater than that produced by conventional doxorubicin treatment, further corroborating the efficacy of combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037341360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037341360&partnerID=8YFLogxK

M3 - Article

C2 - 12631627

AN - SCOPUS:0037341360

VL - 9

SP - 1211

EP - 1217

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -